Cargando…

Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial

BACKGROUND: Benign prostatic enlargement (BPE) causes discomfort in daily life, including lower urinary tract symptoms (LUTSs) caused by the enlarged prostate, and requires long-term management as a chronic, irreversible disease. To improve LUTS, certain complementary therapies have been used with o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hye-Yoon, Bae, Go-Eun, Lee, Sang-Don, Nam, Jong-Kil, Yun, Young-Ju, Han, Ji-Yeon, Lee, Dong-Hoon, Choi, Jun-Young, Park, Seong-Ha, Kwon, Jung-Nam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004691/
https://www.ncbi.nlm.nih.gov/pubmed/31977907
http://dx.doi.org/10.1097/MD.0000000000018918
_version_ 1783494780392570880
author Lee, Hye-Yoon
Bae, Go-Eun
Lee, Sang-Don
Nam, Jong-Kil
Yun, Young-Ju
Han, Ji-Yeon
Lee, Dong-Hoon
Choi, Jun-Young
Park, Seong-Ha
Kwon, Jung-Nam
author_facet Lee, Hye-Yoon
Bae, Go-Eun
Lee, Sang-Don
Nam, Jong-Kil
Yun, Young-Ju
Han, Ji-Yeon
Lee, Dong-Hoon
Choi, Jun-Young
Park, Seong-Ha
Kwon, Jung-Nam
author_sort Lee, Hye-Yoon
collection PubMed
description BACKGROUND: Benign prostatic enlargement (BPE) causes discomfort in daily life, including lower urinary tract symptoms (LUTSs) caused by the enlarged prostate, and requires long-term management as a chronic, irreversible disease. To improve LUTS, certain complementary therapies have been used with or without doctors’ directions. Conventional treatments and complementary therapies tend to be combined unsystematically, depending on patient preference; thus, research for safe and efficient combination therapy is warranted. METHODS: Twenty-nine participants were randomly assigned to an integrative group (IG, n = 15) or a conventional group (CG, n = 14). The IG received moxibustion (twice weekly for 4 weeks, at the acupuncture points SP6, LR3, and CV4) and conventional medication for 4 weeks, followed by conventional medication alone for 8 weeks. The CG received conventional medication alone for 12 weeks. The outcome measures were International Prostate Symptom Score (IPSS), patient's global impression of changes (PGIC), maximum urinary flow rate (Q(max)), postvoid residual urine volume (PVR), and frequency-volume chart. RESULTS: Total IPSS (IG, −2.4 ± 4.2; CG, 0.9 ± 4.0; P = .039), PGIC-A (IG, 3.5 ± 1.0; CG, 2.2 ± 1.0; P = .001), and PGIC-B (IG, 3.5 ± 0.1; CG, 4.7 ± 0.6; P = .004) were significantly improved in the IG compared with the CG, 4 weeks after baseline. Among the IPSS items, incomplete emptying (IG, −0.6 ± 0.7; CG, 0.4 ± 1.2; P = .019), straining (IG, −0.6 ± 0.8; CG, 0.2 ± 1.2; P = .046), and nocturia (IG, −0.8 ± 1.4; CG, 0.1 ± 1.0; P = .045) showed significant differences. The Q(max) and PVR volume did not differ significantly at 12 weeks after the baseline. CONCLUSION: Moxibustion can be considered an adjunct therapy to improve LUTS in BPE patients. A full-sized randomized controlled trial would be feasible with comparator modifications and an extended study period. The study design should include a placebo group and narrow the eligibility to subjects who do not respond well to conventional treatments.
format Online
Article
Text
id pubmed-7004691
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-70046912020-02-18 Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial Lee, Hye-Yoon Bae, Go-Eun Lee, Sang-Don Nam, Jong-Kil Yun, Young-Ju Han, Ji-Yeon Lee, Dong-Hoon Choi, Jun-Young Park, Seong-Ha Kwon, Jung-Nam Medicine (Baltimore) 3800 BACKGROUND: Benign prostatic enlargement (BPE) causes discomfort in daily life, including lower urinary tract symptoms (LUTSs) caused by the enlarged prostate, and requires long-term management as a chronic, irreversible disease. To improve LUTS, certain complementary therapies have been used with or without doctors’ directions. Conventional treatments and complementary therapies tend to be combined unsystematically, depending on patient preference; thus, research for safe and efficient combination therapy is warranted. METHODS: Twenty-nine participants were randomly assigned to an integrative group (IG, n = 15) or a conventional group (CG, n = 14). The IG received moxibustion (twice weekly for 4 weeks, at the acupuncture points SP6, LR3, and CV4) and conventional medication for 4 weeks, followed by conventional medication alone for 8 weeks. The CG received conventional medication alone for 12 weeks. The outcome measures were International Prostate Symptom Score (IPSS), patient's global impression of changes (PGIC), maximum urinary flow rate (Q(max)), postvoid residual urine volume (PVR), and frequency-volume chart. RESULTS: Total IPSS (IG, −2.4 ± 4.2; CG, 0.9 ± 4.0; P = .039), PGIC-A (IG, 3.5 ± 1.0; CG, 2.2 ± 1.0; P = .001), and PGIC-B (IG, 3.5 ± 0.1; CG, 4.7 ± 0.6; P = .004) were significantly improved in the IG compared with the CG, 4 weeks after baseline. Among the IPSS items, incomplete emptying (IG, −0.6 ± 0.7; CG, 0.4 ± 1.2; P = .019), straining (IG, −0.6 ± 0.8; CG, 0.2 ± 1.2; P = .046), and nocturia (IG, −0.8 ± 1.4; CG, 0.1 ± 1.0; P = .045) showed significant differences. The Q(max) and PVR volume did not differ significantly at 12 weeks after the baseline. CONCLUSION: Moxibustion can be considered an adjunct therapy to improve LUTS in BPE patients. A full-sized randomized controlled trial would be feasible with comparator modifications and an extended study period. The study design should include a placebo group and narrow the eligibility to subjects who do not respond well to conventional treatments. Wolters Kluwer Health 2020-01-24 /pmc/articles/PMC7004691/ /pubmed/31977907 http://dx.doi.org/10.1097/MD.0000000000018918 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 3800
Lee, Hye-Yoon
Bae, Go-Eun
Lee, Sang-Don
Nam, Jong-Kil
Yun, Young-Ju
Han, Ji-Yeon
Lee, Dong-Hoon
Choi, Jun-Young
Park, Seong-Ha
Kwon, Jung-Nam
Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial
title Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial
title_full Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial
title_fullStr Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial
title_full_unstemmed Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial
title_short Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial
title_sort moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: a randomized controlled pilot trial
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004691/
https://www.ncbi.nlm.nih.gov/pubmed/31977907
http://dx.doi.org/10.1097/MD.0000000000018918
work_keys_str_mv AT leehyeyoon moxibustionasanadjunctforlowerurinarytractsymptomsassociatedwithbenignprostateenlargementarandomizedcontrolledpilottrial
AT baegoeun moxibustionasanadjunctforlowerurinarytractsymptomsassociatedwithbenignprostateenlargementarandomizedcontrolledpilottrial
AT leesangdon moxibustionasanadjunctforlowerurinarytractsymptomsassociatedwithbenignprostateenlargementarandomizedcontrolledpilottrial
AT namjongkil moxibustionasanadjunctforlowerurinarytractsymptomsassociatedwithbenignprostateenlargementarandomizedcontrolledpilottrial
AT yunyoungju moxibustionasanadjunctforlowerurinarytractsymptomsassociatedwithbenignprostateenlargementarandomizedcontrolledpilottrial
AT hanjiyeon moxibustionasanadjunctforlowerurinarytractsymptomsassociatedwithbenignprostateenlargementarandomizedcontrolledpilottrial
AT leedonghoon moxibustionasanadjunctforlowerurinarytractsymptomsassociatedwithbenignprostateenlargementarandomizedcontrolledpilottrial
AT choijunyoung moxibustionasanadjunctforlowerurinarytractsymptomsassociatedwithbenignprostateenlargementarandomizedcontrolledpilottrial
AT parkseongha moxibustionasanadjunctforlowerurinarytractsymptomsassociatedwithbenignprostateenlargementarandomizedcontrolledpilottrial
AT kwonjungnam moxibustionasanadjunctforlowerurinarytractsymptomsassociatedwithbenignprostateenlargementarandomizedcontrolledpilottrial